Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches

Current Opinion in Oncology

Volumn 25, Issue 6, 2013, Pages 707-715

  Locatelli, Franco ^a,b   Moretta, Francesca ^a   Rutella, Sergio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

acute lymphoblastic leukemia; allogeneic stem cell transplantation; cellular therapies; minimal residual disease; monoclonal antibodies

Indexed keywords

ASPARAGINASE; BLINATUMOMAB; BORTEZOMIB; CD19 ANTIBODY; CD22 ANTIGEN; CD3 ANTIBODY; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLT3 LIGAND; GAMMA INTERFERON; IMATINIB; INOTUZUMAB OZOGAMICIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MOXETUMOMAB PASUDOTOX; NELARABINE; NUCLEOSIDE ANALOG; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; T CELL LYMPHOMA; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84885429550     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000011     Document Type: Review

References (86)

1. Conter V, Arico M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24:255-264.
2. Inaba H, Rubnitz JE, Coustan-Smith E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011; 29:3293-3300.
3. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 2013; 14:e205-e217.
4. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010; 28:2339-2347.
5. Herold R, von Stackelberg A, Hartmann R, et al. Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference. J Clin Oncol 2004; 22:569-570.
6. Gaynon PS, Harris RE, Altman AJ, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol 2006; 24:3150-3156.
7. Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse-the Children's Cancer Group Experience. Cancer 1998; 82:1387-1395.
8. Bailey LC, Lange BJ, Rheingold SR, Bunin NJ. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol 2008; 9:873-883.
9. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010; 376:2009-2017.
10. Henze G, Fengler R, Hartmann R, et al. Six-year experience with a compre hensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991; 78:1166-1172.
11. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012; 120:2807-2816.
12. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005; 131:579-587.
13. Einsiedel HG, von Stackelberg A, Hartmann R, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005; 23:7942-7950.
14. Guerrouahen BS, Wieder E, Blanchard EG, et al. Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib. Pediatr Blood Cancer 2009; 53:1132-1135.
15. Paganin M, Zecca M, Fabbri G, et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia 2008; 22:2193-2200.
16. Eckert C, Biondi A, Seeger K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001; 358:1239-1241.
17. Coustan-Smith E, Gajjar A, Hijiya N, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 2004; 18:499-504.
18. Bader P, Kreyenberg H, Henze GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27:377-384.
19. Barrett AJ, Horowitz MM, Pollock BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994; 331:1253-1258.
20. Locatelli F, Zecca M, Messina C, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hema-topoietic stem cell transplantation from unrelated donors. Leukemia 2002; 16:2228-2237.
21. Uderzo C, Valsecchi MG, Bacigalupo A, et al. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 1995; 13:352-358.
22. Borgmann A, von Stackelberg A, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lympho-blastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101:3835-3839.
23. Dini G, Zecca M, Balduzzi A, et al. No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood 2011; 118:6683-6690.
24. Ruggeri A, Michel G, Dalle JH, et al. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission. An Eurocord, PDWP-EBMT analysis. Leukemia 2012; 12:.
25. Saarinen-Pihkala UM, Gustafsson G, Ringden O, et al. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lympho-blastic leukemia in second remission. J Clin Oncol 2001; 19:3406-3414.
26. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97:2962-2971.
27. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369:1947-1954.
28. Smith AR, Baker KS, Defor TE, et al. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors. Biol Blood Marrow Transplant 2009; 15:1086-1093.
29. Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant 2008; 41:207-214.
30. Moretta L, Locatelli F, Pende D, et al. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011; 117:764-771.
31. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2100.
32. Pende D, Marcenaro S, Falco M, et al. Antileukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 113:3119-3129.
33. Klingebiel T, Cornish J, Labopin M, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010; 115:3437-3446.
34. Jeha S. New therapeutic strategies in acute lymphoblastic leukemia. Semin Hematol 2009; 46:76-88.
35. Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 2007; 6:149-165.
36. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103:784-789.
37. Kantarjian HM, Jeha S, Gandhi V, et al. Clofarabine: past, present, and future. Leuk Lymphoma 2007; 48:1922-1930.
38. Pui CH, Jeha S. Clofarabine. Nat Rev Drug Discov 2005; (Suppl):S12-S13.
39. Faderl S, Gandhi V, Keating MJ, et al. The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer 2005; 103:1985-1995.
40. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24:1917-1923.
41. Hijiya N, Gaynon P, Barry E, et al. A multicenter phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009; 23:2259-2264.
42. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011; 118:6043-6049.
43. Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 2009; 147:371-378.
44. O'Connor D, Sibson K, Caswell M, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br J Haematol 2011; 154:482-485.
45. Beesley AH, Palmer ML, Ford J, et al. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. Br J Haematol 2007; 137:109-116.
46. Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005; 23:3396-3403.
47. Berg SL, Blaney SM, Devidas M, et al. PhaseIIstudy of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005; 23:3376-3382.
48. Cohen MH, Johnson JR, Massie T, et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 2006; 12:5329-5335.
49. Dunsmore KP, Devidas M, Linda SB, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lympho-blastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:2753-2759.
50. Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 2003; 9:3991S-3994S.
51. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 2008; 26:3756-3762.
52. Raetz EA, Cairo MS, Borowitz MJ, et al. Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from Children's Oncology Group (COG) study ADVL04P2. ASH Annual Meeting Abstracts 2011; 118:573.
53. Wayne AS, Bhojwani D, Silverman LB, et al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL). ASH Annual Meeting Abstracts 2011; 118:248.
54. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lympho-cytic leukaemia: a phase 2 study. Lancet Oncol 2012; 13:403-411.
55. Loffler A, Kufer P, Lutterbuse R, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxi-city by unstimulated T lymphocytes. Blood 2000; 95:2098-2103.
56. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cyto-toxicity. Proc Natl Acad Sci U S A 1995; 92:7021-7025.
57. Brandl C, Haas C, d'Argouges S, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Im-munother 2007; 56:1551-1563.
58. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-977.
59. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacological response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119:6226-6233.
60. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-2498.
61. Topp MS, Goekbuget N, Zugmaier G, et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: updated results of an ongoing phase II trial. ASH Annual Meeting Abstracts 2011; 118:252.
62. Handgretinger R, Zugmaier G, Henze G, et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with posttransplant relapsed acute lymphoblastic leukemia. Leukemia 2011; 25:181-184.
63. Gore L, Zugmaier G, Handgretinger R, et al. Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL). J Clin Oncol 2013; 31:A10007.
64. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer 2010; 55:254-259.
65. Horton TM, Pati D, Plon SE, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res 2007; 13:1516-1522.
66. Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Ther apeutic Advances in Childhood Leukemia Lymphoma (TACL) Study. Blood 2012; 120:285-290.
67. Hunger SP. Tyrosine kinase inhibitor use in pediatric Philadelphia chromo some-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011:361-365.
68. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009; 27:5175-5181.
69. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012; 13:936-945.
70. Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011; 118:6521-6528.
71. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hemato-logic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110:2309-2315.
72. Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharma-cokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol 2011; 29:839-844.
73. Glover JM, Loriaux M, Tyner JW, et al. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 59:576-579.
74. Small D. Targeting FLT3 for the treatment of leukemia. Semin Hematol 2008; 45:S17-S21.
75. Stam RW, den Boer ML, Schneider P, et al. Targeting FLT3 in primary MLL-gene-rearrangedinfantacutelymphoblasticleukemia.Blood 2005;106:2484-2490.
76. Brown P, Levis M, Shurtleff S, et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005; 105:812-820.
77. Torelli GF, Guarini A, Porzia A, et al. FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia. Br J Haematol 2005; 130:43-50.
78. Schult C, Dahlhaus M, Ruck S, et al. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via cas-pase 3, 7 and PARP in B-and T-lymphoblastic cells. BMC Cancer 2010; 10:560.
79. Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG. Targeted im-munotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother 2012; 61:953-962.
80. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118:4817-4828.
81. Brentjens RJ, Curran KJ. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology Am Soc Hematol Educ Program 2012; 2012:143-151.
82. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007; 13:5426-5435.
83. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116:4099-4102.
84. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-733.
85. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lympho-blastic leukemia. Sci Transl Med 2013; 5:177.
86. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-1518.